Neosperidin dihydrochalcone
(Synonyms: 新橙皮苷二氢查尔酮; Neohesperidin DC; NHDC) 目录号 : GN10550
A semisynthetic glycoside chalcone and artificial sweetener
Cas No.:20702-77-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | WST-8 dye is used in the cell viability assay. HIT-T15 and HUVEC cells are grown and maintained in Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal bovine calf serum. 1000 cells in each well are incubated with various concentrations of neohesperidin dihydrochalcone (50, 100, 500 μM, 1 mM) and other compounds. After treating HIT-T15 and HUVEC cells with 500 μM HOCl, WST-8 dye is added to each well, and the absorbance is detected at 420 nm with microplate reader[1]. |
Animal experiment: | Rats: The embryotoxicity/teratogenicity of neohesperidin dihydrochalcone is examined in Wistar Crl:(WI)WU BR rats. The study is comprised of four groups of 28 mated female rats each, i.e., a control group (0% neohesperidin dihydrochalcone) and three treatment groups (1.25, 2.5, and 5% neohesperidin dihydrochalcone). The general condition and behavior of the animals are observed twice daily. Body weight is determined on days 0, 7, 14, and 21 of gestation. Food consumption is determined during three consecutive periods (days 0-7, 7-14, and 14-21 of gestation)[4]. [3]Mice: Neohesperidin dihydrochalcone is dissolved in a 0.5% CMC vehicle. Mice are randomized into four groups. The control group receives equal volume of vehicles throughout. The PQ group receives saline once daily for 6 consecutive days. One hour after final saline treatment, mice are injected with PQ (75 mg/kg body weight). The neohesperidin dihydrochalcone group receives a daily dose of 200 mg/kg body weight by oral gavage for 6 consecutive days. One hour after final neohesperidin dihydrochalcone treatment, mice are injected with PQ (75 mg/kg body weight)[3]. |
References: [1]. Choi JM, et al. Antioxidant properties of neohesperidin dihydrochalcone: inhibition of hypochlorous acid-induced DNA strand breakage, protein degradation, and cell death. Biol Pharm Bull. 2007 Feb;30(2):324-30. | |
Neohesperidin dihydrochalcone is a synthetic glycoside chalcone, is added to various foods and beverages as a low caloric artificial sweetener.
Neohesperidin dihydrochalcone shows remarkable radical scavenging activity against stable radical and reactive oxygen species (ROS) in concentration dependent manner. Especially, neohesperidin dihydrochalcone is the most potent inhibitor of H2O2 and HOCl. Neohesperidin dihydrochalcone shows HOCl scavenging activity of 93.5% and H2O2 scavenging property of 73.5%. Neohesperidin dihydrochalcone shows extensive inhibitory effect especially on non-radical ROS H2O2 and HOCl with IC50 values of 205.1, 25.5 μM[1]. Neohesperidin dihydrochalcone is found to be an activator of porcine pancreatic alpha-amylase (PPA) with an IC50 of 389 μM[2].
Neohesperidin dihydrochalcone administration results in significant reduction in activities of two useful markers of liver damage, AST and ALT. The relative levels of NF-κB, IL-6, IL-1β and TNF-α protein in the liver of PQ-treated mice are inhibited by neohesperidin dihydrochalcone[3]. The embryotoxicity/teratogenicity of neohesperidin dihydrochalcone is examined in Wistar Crl:(WI)WU BR rats. No adverse effects are observed at neohesperidin dihydrochalcone levels of up to 5% of the diet, the highest dose level tested, at which the rats consumed about 3.3 g/kg body weight/day[4].
References:
[1]. Choi JM, et al. Antioxidant properties of neohesperidin dihydrochalcone: inhibition of hypochlorous acid-induced DNA strand breakage, protein degradation, and cell death. Biol Pharm Bull. 2007 Feb;30(2):324-30.
[2]. Kashani-Amin E, et al. Neohesperidin dihydrochalcone: presentation of a small molecule activator of mammalian alpha-amylase as an allosteric effector. FEBS Lett. 2013 Mar 18;587(6):652-8.
[3]. Shi Q, et al. Artificial sweetener neohesperidin dihydrochalcone showed antioxidative, anti-inflammatory and anti-apoptosis effects against paraquat-induced liver injury in mice. Int Immunopharmacol. 2015 Dec;29(2):722-9.
[4]. Waalkens-Berendsen DH, et al. Embryotoxicity and teratogenicity study with neohesperidin dihydrochalcone in rats. Regul Toxicol Pharmacol. 2004 Aug;40(1):74-9.
| Cas No. | 20702-77-6 | SDF | |
| 别名 | 新橙皮苷二氢查尔酮; Neohesperidin DC; NHDC | ||
| 化学名 | 1-[4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)propan-1-one | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C(C(=C3)O)C(=O)CCC4=CC(=C(C=C4)OC)O)O)CO)O)O)O)O)O | ||
| 分子式 | C28H36O15 | 分子量 | 612.21 |
| 溶解度 | ≥ 22.6mg/mL in DMSO | 储存条件 | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6334 mL | 8.1671 mL | 16.3343 mL |
| 5 mM | 0.3267 mL | 1.6334 mL | 3.2669 mL |
| 10 mM | 0.1633 mL | 0.8167 mL | 1.6334 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。